Not available in the U.S.
Betahistine
SERC
What it isH3 antagonist and weak H1 agonist; Meniere disease.
Why this oneIt is standard therapy for Meniere vertigo across Europe and Canada.
What limits itA large randomized trial found no benefit over placebo. Not US-approved.
FDA-approved for
- Meniere disease (non-US)
Off-label
- Meniere disease (approved in Europe and Canada)
NO BOXED WARNINGS
Principal riskA large randomized trial found no benefit over placebo
Classes and tags
Clinical profile
Mechanism of action: Betahistine ballicule
Open Betahistine in the interactive console ↗
Memory aids: mascots and interaction avatars
Legos → theme for H3 antihistamine